$2.60
29.35% day before yesterday
Nasdaq, Apr 03, 03:30 pm CET
ISIN
CA03835T2002
Symbol
APTO
Sector
Industry

Aptose Biosciences Inc. Stock price

$3.00
-0.64 17.58% 1M
-8.16 73.12% 6M
-3.76 55.61% YTD
-39.90 93.01% 1Y
-658.50 99.55% 3Y
-2,724.00 99.89% 5Y
-2,517.00 99.88% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
+0.40 15.38%
ISIN
CA03835T2002
Symbol
APTO
Sector
Industry

Key metrics

Market capitalization $7.66m
Enterprise Value $11.59m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-26.26m
Cash position $6.71m
EPS (TTM) EPS $-47.03
Short interest 2.60%

Is Aptose Biosciences Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Aptose Biosciences Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Aptose Biosciences Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Aptose Biosciences Inc.:

Buy
100%

Financial data from Aptose Biosciences Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.42 0.42
11% 11%
-
-0.42 -0.42
11% 11%
-
- Selling and Administrative Expenses 25 25
73% 73%
-
- Research and Development Expense - -
-
-
-26 -26
50% 50%
-
- Depreciation and Amortization 0.42 0.42
11% 11%
-
EBIT (Operating Income) EBIT -26 -26
50% 50%
-
Net Profit -25 -25
50% 50%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aptose Biosciences Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aptose Biosciences Inc. Stock News

Neutral
GlobeNewsWire
8 days ago
Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy Aptose Signs Debt Conversion Agreement with Hanmi SAN DIEGO and TORONTO, March 28, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology c...
Neutral
GlobeNewsWire
19 days ago
SAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that it received a written notification from the Listing Qualifi...
Neutral
GlobeNewsWire
about one month ago
Aptose Announces Positive Clinical Safety Review and Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib
More Aptose Biosciences Inc. News

Company Profile

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

Head office Canada
CEO William Rice
Employees 13
Founded 1986
Website www.aptose.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today